Published in Blood on September 01, 1975
Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin. J Clin Invest (1977) 1.21
Factor VIII/von Willebrand factor protein. Galactose a cryptic determinant of von Willebrand factor activity. J Clin Invest (1978) 0.96
Effect of dextran on factor VIII (antihemophilic factor) and platelet function. Ann Surg (1979) 0.93
The platelet: life on the razor's edge between hemorrhage and thrombosis. Transfusion (2014) 0.75
Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol (1976) 13.98
Proposals for the classification of the myelodysplastic syndromes. Br J Haematol (1982) 10.90
Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med (1985) 6.82
Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest (1999) 5.65
NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med (1982) 4.70
A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest (1983) 3.05
A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest (1985) 2.72
Novel function for beta 1 integrins in keratinocyte cell-cell interactions. J Cell Biol (1990) 2.39
Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO) Br J Haematol (1991) 2.23
Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest (1988) 2.23
Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med (1985) 2.22
Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol (1989) 2.13
Hemostasis in the mouse (Mus musculus): a review. Thromb Haemost (1999) 2.13
Studies on the purification and characterization of human factor 8. J Clin Invest (1972) 1.97
Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood (1985) 1.95
Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia. Blood (1980) 1.80
Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood (2000) 1.77
Heterogeneity of human whole blood platelet subpopulations. I. Relationship between buoyant density, cell volume, and ultrastructure. Blood (1977) 1.69
American Burkitt's lymphoma: a clinicopathologic study of 30 cases. II. Pathologic correlations. Am J Med (1975) 1.65
The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol (1981) 1.64
Coombs' positive reactions associated with sodium cephalothin therapy. JAMA (1967) 1.52
Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood (1996) 1.52
Variable protection of beta 3-integrin--deficient mice from thrombosis initiated by different mechanisms. Blood (2001) 1.47
In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation (1997) 1.46
Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest (1996) 1.39
Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukaemia. Br J Haematol (1973) 1.36
Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor. Blood (1992) 1.28
Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation (2001) 1.27
Frequencies and patterns of bone marrow involvement in non-Hodgkin lymphomas: observations on the value of bilateral biopsies. Am J Hematol (1977) 1.27
Measuring faculty effort and contributions in medical education. Acad Med (2000) 1.26
The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domain. J Clin Invest (1991) 1.26
Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation (1988) 1.25
A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood (1981) 1.25
Asialo von Willebrand factor interactions with platelets. Interdependence of glycoproteins Ib and IIb/IIIa for binding and aggregation. J Clin Invest (1985) 1.22
Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood (1994) 1.21
Fibrinogen competes with von Willebrand factor for binding to the glycoprotein IIb/IIIa complex when platelets are stimulated with thrombin. Blood (1984) 1.21
Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin. J Clin Invest (1977) 1.21
The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol (1986) 1.20
Effect of multimeric structure of the factor VIII/von Willebrand factor protein on binding to platelets. Blood (1981) 1.20
Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine. Ann Intern Med (1988) 1.19
American Burkitt's lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival. Am J Med (1975) 1.15
Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest (1988) 1.14
Von Willebrand's disease: combined qualitative and quantitative abnormalities. N Engl J Med (1977) 1.14
Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood (1985) 1.13
Translational careers. Science (2009) 1.13
A model of fulminant hepatic failure in the rabbit. Gastroenterology (1978) 1.12
Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation (1999) 1.12
The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci U S A (1991) 1.12
Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest (1990) 1.12
Evidence that platelet glycoprotein IIIa has a large disulfide-bonded loop that is susceptible to proteolytic cleavage. J Biol Chem (1989) 1.11
Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood (1986) 1.11
A variant form of hypergranular promyelocytic leukaemia (M3) Br J Haematol (1980) 1.09
Characteristics of blast crisis in chronic granulocytic leukemia. Blood (1977) 1.09
Studies on the Factor VIII/von Willebrand factor antigen on human platelets. Thromb Res (1975) 1.08
In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIa von Willebrand's disease. Proc Natl Acad Sci U S A (1985) 1.08
Poisson statistical analysis of repetitive subcloning by the limiting dilution technique as a way of assessing hybridoma monoclonality. Methods Enzymol (1986) 1.08
Defibrination in acute pancreatitis. Ann Intern Med (1972) 1.08
Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost (2011) 1.07
Heparin-induced thrombocytopenia: confirmation of diagnosis with in vitro methods. Blood (1975) 1.06
Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release. J Clin Invest (1971) 1.06
Fibrinogen coating density affects the conformation of immobilized fibrinogen: implications for platelet adhesion and spreading. Thromb Haemost (1998) 1.06
Reversible decrease in platelet retention by glass bead columns (adhesiveness) induced by disturbing the blood. Proc Soc Exp Biol Med (1971) 1.06
Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (alphaIIbbeta3) and other proteins from hamster-mouse interspecies hybridomas. Biochem Biophys Res Commun (1999) 1.05
Hematologically important mutations: Glanzmann thrombasthenia. Blood Cells Mol Dis (1997) 1.04
Studies of the human factor VIII/von Willebrand factor protein. III. Qualitative defects in von Willebrand's disease. J Clin Invest (1975) 1.03
Thrombocytopenia with sodium cephalothin therapy. Ann Intern Med (1972) 1.02
Activation affects access to the platelet receptor for adhesive glycoproteins. J Cell Biol (1986) 1.02
Danazol increases factor VIII and factor IX in classic hemophilia and Christmas disease. N Engl J Med (1983) 1.02
Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder. N Engl J Med (1984) 1.02
Evidence that glycocalicin circulates in normal plasma. J Clin Invest (1984) 1.02
Polyclonal B-cell lymphocytosis and hypergammaglobulinemia in patients with Gaucher disease. Am J Hematol (1988) 1.01
Carbohydrate deficiency of the factor VIII/von Willebrand factor Protein in von Willebrand's disease variants. Science (1976) 1.01
The effects of ristocetin and von Willebrand factor on platelet electrophoretic mobility. J Clin Invest (1978) 1.01
Immunological studies of factor VIII in haemophilia and von Willebrand's disease. Nat New Biol (1973) 1.00
The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation. J Clin Invest (1993) 1.00
Statistical analysis of repetitive subcloning by the limiting dilution technique with a view toward ensuring hybridoma monoclonality. Hybridoma (1983) 1.00
Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med (1991) 1.00
Altered processing of integrin receptors during keratinocyte activation. Exp Cell Res (1991) 1.00
The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol (1995) 0.99
Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure. Am J Med (1979) 0.99
Intravascular coagulation in acute leukemia: clinical and subclinical abnormalities. Blood (1972) 0.98
Acquired type I hyperlipoproteinemia with systemic lupus erythematosus, dysglobulinemia and heparin resistance. Am J Med (1969) 0.97
Factor VIII/von Willebrand factor protein. Galactose a cryptic determinant of von Willebrand factor activity. J Clin Invest (1978) 0.96
Noncardiovascular findings associated with heart disease in the idiopathic hypereosinophilic syndrome. Am J Cardiol (1983) 0.96
Plasma cofactors of platelet function: correlation with diabetic retinopathy and hemoglobins Ala-c. Ann Intern Med (1978) 0.95
Acute promyelocytic leukemia: a model for understanding the role of the malignant cell in hemostasis. Hum Pathol (1974) 0.95